Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.
Surg Endosc. 2019 Apr;33(4):1180-1188. doi: 10.1007/s00464-018-6392-9. Epub 2018 Aug 23.
Endoscopic ampullectomy has been recognized as a safe and reliable means to resect selective tumors of the ampulla of Vater and is associated with lower morbidity and mortality rates compared to surgical resection. Success rates range from 42 to 92%, with recurrences reported in up to 33%. Studies on endoscopic resection of advanced lesions such as those with intraductal extension of adenoma (IEA) and lateral spreading adenomas (LSA) are limited. We aimed to evaluate the technical success, complications, and recurrence of endoscopic resection of ampullary adenomas, including advanced lesions.
All patients referred to the Erasmus Medical Center for endoscopic resection of an ampullary lesion were retrospectively identified between 2002 and 2016. Endoscopic success was defined as complete excision of the adenoma, irrespective of the number of attempts, in the absence of recurrence.
We included 87 patients with a median age of 65 years. Of these, 56 patients (64%) had an adenoma confined to the ampulla (ACA), 20 patients (23%) had an LSA, and 11 patients (13%) were treated for an IEA. The median lesion sizes were 24.6 mm, 41.4 mm, and 16.3 mm, respectively (P < 0.001). Complications occurred in 22 patients (25.3%), of which hemorrhage was most prevalent (12.6%), followed by perforation (8.1%). Complications were equally divided (P = 0.874). The median follow-up duration was 21.1 months (12-45.9) for ACA, 14.7 months (4.2-34.5) for LSA, and 5.8 months (3.7-22.0) for IEA (P = 0.051). Endoscopic resection was curative in 87.5% of patients with an ACA, 85% in patients with an LSA, and in only one patient with an IEA (P < 0.001). Recurrence occurred in 10 patients (11.5%) (P = 0.733).
Endoscopic ampullectomy is safe and highly successful in selected patients with an adenoma with or without lateral spreading. Outcomes of endoscopic treatment adenomas with an intraductal extension are less favorable and in these cases surgery should be considered.
内镜乳头切开术已被认为是安全可靠的方法,可切除选择性的 Vater 壶腹肿瘤,与手术切除相比,其发病率和死亡率较低。成功率范围为 42%至 92%,报道的复发率为 33%。关于内镜切除高级病变(如具有管内延伸的腺瘤(IEA)和侧向扩散腺瘤(LSA))的研究有限。我们旨在评估内镜切除包括高级病变在内的壶腹腺瘤的技术成功率、并发症和复发率。
回顾性分析 2002 年至 2016 年间,所有因壶腹病变接受内镜切除术的患者。内镜成功定义为无论尝试次数如何,只要腺瘤完全切除且无复发,即视为成功。
我们纳入了 87 例中位年龄为 65 岁的患者。其中,56 例(64%)患者的腺瘤局限于壶腹(ACA),20 例(23%)患者为 LSA,11 例(13%)患者为 IEA 治疗。中位病变大小分别为 24.6 毫米、41.4 毫米和 16.3 毫米(P<0.001)。22 例患者(25.3%)发生并发症,其中最常见的是出血(12.6%),其次是穿孔(8.1%)。并发症发生率相当(P=0.874)。ACA 的中位随访时间为 21.1 个月(12-45.9),LSA 为 14.7 个月(4.2-34.5),IEA 为 5.8 个月(3.7-22.0)(P=0.051)。内镜切除在 87.5%的 ACA 患者中是治愈性的,在 85%的 LSA 患者中也是治愈性的,而在仅有 1 例 IEA 患者中是治愈性的(P<0.001)。10 例(11.5%)患者复发(P=0.733)。
内镜乳头切开术在选择的腺瘤患者中是安全且高度成功的,无论是否存在侧向扩散。内镜治疗具有管内延伸的腺瘤的结果不太理想,在这些情况下应考虑手术治疗。